Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter

American Journal of Pathology

Volumn 155, Issue 2, 1999, Pages 387-394

  Fujisawa, Hironori ^a   Kurrer, Michael ^b   Reis, Rui M ^a   Yonekawa, Yasuhiro ^b   Kleihues, Paul ^a,b   Ohgaki, Hiroko ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; GLIAL FIBRILLARY ACIDIC PROTEIN;

ADULT; AGED; ALLELE; ARTICLE; CANCER GRADING; CHROMOSOME 10Q; CHROMOSOME 19; CLINICAL ARTICLE; FEMALE; GENETIC POLYMORPHISM; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

EID: 0032788101     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65135-8     Document Type: Article

References (53)

1. Lantos PL, VandenBerg SR, Kleihues P: Tumours of the nervous system. Greenfield's Neuropathology. Edited by DI Graham, PL Lantos. London, Arnold, 1996, pp 583-879
2. Leenstra S, Oskam NT, Bijleveld EH, Bosch DA, Troost D, Hulsebos TJM: Genetic sub-types of human malignant astrocytoma correlate with survival. Int J Cancer 1998, 79:159-165
3. Galanis E, Buckner JC, Dinapoli RP, Scheithauer BW, Jenkins RB, Wang CH, O'Fallon JR, Farr G, Jr: Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results. J Neurosurg 1998, 89:425-430
4. Kleihues P, Ohgaki H: Genetics of glioma progression and the definition of primary and secondary glioblastoma. Brain Pathol 1997, 7:1131-1136
5. Kleihues P, Ohgaki H: Primary and secondary glioblastoma: from concept to clinical diagnosis. Neuro-Oncology 1999, 1:44-51
6. Rasheed BK, McLendon RE, Friedman HS, Friedman AH, Fuchs HE, Bigner DD, Bigner SH: Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25. Oncogene 1995, 10: 2243-2246
7. Albarosa R, Colombo BM, Roz L, Magnani I, Polio B, Cirenei N, Giani C, Conti AMF, DiDonato S, Finocchiaro G: Deletion mapping of gliomas suggests the presence of two small regions for candidate tumor-suppressor genes in a 17-cM interval on chromosome 10q. Am J Hum Genet 1996, 58:1260-1267
8. Voesten AMJ, Bijleveld EH, Westerveld A, Hulsebos TJM: Fine mapping of a region of common deletion on chromosome arm 10p in human glioma. Genes Chromosomes Cancer 1997, 20:167-172
9. Kon H, Sonoda Y, Kumabe T, Yoshimoto T, Sekiya T, Murakami Y: Structural and functional evidence for the presence of tumor suppressor genes on the short arm of chromosome 10 in human gliomas. Oncogene 1997, 16:257-263
10. Maier D, Comparone D, Taylor E, Zhang Z, Gratzl O, Van Meir EG, Scott RJ, Merlo A: New deletion in low-grade oligodendroglioma at the glioblastoma suppressor locus on chromosome 10q25-26. Oncogene 1997, 15:997-1000
11. Fults D, Redone CA, Thompson GE, Uchiyama CM, Gumpper KL, Iliev D, Vinson VL, Tavtigian SV, Perry WL: Microsatellite deletion mapping on chromosome 10q and mutation analysis of MMAC1, FAS, and MXl1 in human glioblastoma multiforme. Int J Oncol 1998, 12: 905-910
12. Ichimura K, Schmidt EE, Miyakawa A, Goike HM, Collins VP: Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades. Genes Chromosomes Cancer 1998, 22:9-15
13. Karlbom AE, James CD. Boethius J. Cavenee WK, Collins VP, Nordenskjöld M, Larsson C: Loss of heterozygosity in malignant gliomas involves at least three distinct regions on chromosome 10. Hum Genet 1993, 92:169-174
14. Sonoda Y, Murakami Y, Tominaga T, Kayama T, Yoshimoto T, Sekiya T: Deletion mapping of chromosome 10 in human glioma. Jpn J Cancer Res 1996, 87:363-367
15. Kimmelman AC, Ross DA, Liang BC: Loss of heterozygosity of chromosome 10p in human gliomas. Genomics 1996, 34:250-254
16. Wang SI, Puc J, Li J, Bruce JN, Cairns P, Sidransky D, Parsons R: Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 1997, 57:4183-4186
17. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947
18. Steck PA, Pershouse MA, Jasser SA, Yung WKA, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DHF, Tavtigian SV: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997, 15:356-362
19. Boström J, Cobbers JM, Wolter M, Tabatabai G, Weber RG, Lichter P, Collins VP, Reifenberger G: Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q. Cancer Res 1998, 58:29-33
20. Chiariello E, Roz L, Albarosa R, Magnani I, Finocchiaro G: PTEN/MMAC1 mutations in primary glioblastomas, and short-term cultures of malignant gliomas. Oncogene 1998, 16:541-545
21. Duerr E-M, Rollbrocker B, Hayashi Y, Peters N, Meyer-Puttlitz B, Louis DN, Schramm J, Wiestler OD, Parsons R, Eng C, von Deimling A: PTEN mutations in gliomas, and glioneuronal tumors. Oncogene 1998, 16:2259-2264
22. Maier D, Zhang Z, Taylor E, Hamou MF, Gratzl O, Van Meir EG, Scott RJ, Merlo A: Somatic deletion mapping on chromosome 10 and sequence analysis of PTEN/MMAC1 point to the 10q25-26 region as the primary target in low-grade and high-grade gliomas. Oncogene 1998, 16:3331-3335
23. Rasheed BK, Stenzel TT, McLendon RE, Parsons R, Friedman AH, Friedman HS, Bigner DD, Bigner SH: PTEN gene mutations are seen in high-grade but not in low-grade gliomas: Cancer Res 1997, 57: 4187-4190
24. Tohma Y, Gratas C, Biernat W, Peraud A, Fukuda M, Yonekawa Y, Kleihues P, Ohgaki H: PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J Neuropath Exp Neurol 1998, 57:684-689
25. Lang FF, Miller DC, Koslow M, Newcomb EW: Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. J Neurosurg 1994, 81:427-436
26. Fults D, Brockmeyer D, Tullous MW, Pedone CA, Cawthon RM: p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression. Cancer Res 1992, 52:674-679
27. von Deimling A, Louis DN, von Ammon K, Petersen I, Wiestler OD, Seizinger BR: Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas. Cancer Res 1992, 52:4277-4279
28. von Deimling A, Nagel J, Bender B, Lenartz D, Schramm J, Louis DN, Wiestler OD: Deletion mapping of chromosome 19 in human gliomas. Int J Cancer 1994, 57:676-680
29. Rubio MP, Correa KM, Ueki K, Mohrenweiser HW, Gusella JF, von Deimling A. Louis DN: The putative glioma tumor suppressor gene on chromosome 19q maps between APOC2 and HRC. Cancer Res 1994, 54:4760-4763
30. Ritland SR, Ganju V, Jenkins RB: Region-specific loss of heterozygosity on chromosome 19 is related to the morphologic type of human glioma. Genes Chromosomes Cancer 1995, 12:277-282
31. Rosenberg JE, Lisle DK, Burwick JA, Ueki K, von Deimling A, Mohrenweiser HW, Louis DN: Refined deletion mapping of the chromosome 19q glioma tumor suppressor gene to the D19S412-STD interval. Oncogene 1996, 13:2483-2485
32. Yong WH, Chou D, Ueki K, Harsh GR, von Deimling A, Gusella JF, Mohrenweiser HW, Louis DN: Chromosome 19q deletions in human gliomas overlap telomeric to D19S219, and may target a 425 kb region centromeric to D19S112. J Neuropathol Exp Neurol 1995, 54:622-626
33. Histological typing of tumours of the central nervous system. World Health Organization International Histological Classification of Tumours. Edited by Kleihues P, Burger PC, Scheithauer BW: Berlin, Springer Verlag, 1993
34. Watanabe K, Tachibana O, Sato K, Yonekawa Y, Kleihues P, Ohgaki H: Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996, 6:217-224
35. Collins A, Frezal J, Teague J, Morton NE: A metric map of humans: 23,500 loci in 850 bands. Proc Natl Acad Sci USA 1996, 93:14771-14775
36. Watanabe K, Peraud A, Gratas C, Wakai S, Kleihues P, Ohgaki H: p53, and PTEN gene mutations in gemistocytic astrocytomas. Acta Neuropathol 1998, 95:559-564
37. Mollenhauer J, Wiemann S, Scheurlen W, Korn B, Hayashi Y, Wilgenbus KK, von Deimling A, Poustka A: DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours. Nat Genet 1997, 17:32-39
38. Moschonas NK, Spurr NK, Mao J: Report of the first international workshop on human chromosome 10 mapping 1995. Cytogenet Cell Genet 1996, 72:100-112
39. Burger PC, Scheithauer BW: Tumors of the Central Nervous System. Washington, DC, Armed Forces Institute of Pathology, 1994
40. Schmitt HP: Rapid anaplastic transformation in gliomas of adulthood: "selection" in neuro-oncogenesis. Pathol Res Pract 1983, 176:313-323
41. Pathology and Genetics of Tumours of the Nervous System. Edited by Kleinhues P and Cavenee WK. Lyon, International Agency for Research on Cancer, 1997
42. Scherer E: Neoplastic progression in experimental hepatocarcinogenesis. Biochim Biophys Acta 1984, 738:219-236
43. Scherer E: Relationship among histochemically distinguishable early lesions in multistep-multistage hepatocarcinogenesis. Arch Toxicol Suppl 1987, 10:81-94
44. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, Kimura S, Miyamura T, Koike K: The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998, 4:1065-1067
45. Oda T, Tsuda H, Sakamoto M, Hirohashi S: Different mutations of the p53 gene in nodule-in-nodule hepatocellular carcinoma as a evidence for multistage progression. Cancer Lett 1994, 83:197-200
46. Miki T, Bottaro DP, Fleming TP, Smith CL, Burgess WH, Chan AML, Aaronson SA: Determination of ligand-binding specificity by alternative splicing: two distinct growth factor receptors encoded by a single gene. Proc Natl Acad Sci USA 1992, 89:246-250
47. Yamaguchi F, Saya H, Bruner JM, Morrison RS: Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas. Proc Natl Acad Sci USA 1994, 91:484-488
48. Gil Diez de Medina S, Chopin D, El Marjou A, Delouvee A, LaRochelle WJ, Hoznek A, Abbou C, Aaronson SA, Thiery JP, Radvanyi F: Decreased expression of keratinocyte growth factor receptor in a subset of human transitional cell bladder carcinomas. Oncogene 1997, 14: 323-330
49. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, Jen J, Isaacs WB, Bova GS, Sidransky D: Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 1997, 57: 4997-5000
50. Cairns P, Evron E, Okami K, Halachmi N, Esteller M, Herman JG, Bose S, Wang SI, Parsons R, Sidransky D: Point mutation and homozygous deletion of PTEN/MAC1 in primary bladder cancers. Oncogene 1998, 16:3215-3218
51. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP: Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994, 145:1175-1190
52. Hulsebos TJM, Oskam NT, Troost D, Leenstra S, Bijleveld EH: Dynamics of genetic alterations associated with glioma recurrence. Genes Chromosomes Cancer 1998, 23:153-158
53. Macintosh CA, Stower M, Reid N, Maitland NJ: Precise microdissection of human prostate cancers reveals genotypic heterogeneity. Cancer Res 1998, 58:23-28